Drugs · acquisition-cost intelligence
Zembrace SymTouch
Sumatriptan Succinate· ingredient sumatriptan· SUMATRIPTAN SUCCINATE 3 mg/1; SUMATRIPTAN SUCCINATE 3 mg/.5mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$384.03
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per ML — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other sumatriptan products, cheapest acquisition cost first. Per ML — confirm strength/form equivalence before switching.
| Product | NADAC / ML | vs this |
|---|---|---|
| Sumatriptan | $0.34058 | −$383.69 |
| Treximet | $11.67 | −$372.35 |
| Sumatriptan | $15.06 | −$368.97 |
| sumatriptan | $16.06 | −$367.96 |
| sumatriptan | $17.57 | −$366.46 |
| sumatriptan | $69.54 | −$314.49 |
| IMITREX | $72.50 | −$311.53 |
| Tosymra | $108.15 | −$275.87 |
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.